<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200114046127N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-02-20</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Postoperative Chronic Pain and Quality of Life following Laparoscopic Trans-Abdominal Preperitoneal (TAPP) Inguinal Hernia Surgery</public_title>
      <acronym></acronym>
      <scientific_title>Randomised Clinical Trial on Postoperative Chronic Pain and Quality of Life following Laparoscopic Trans-Abdominal Preperitoneal (TAPP) Inguinal Hernia Surgery; a Comparison between Mesh Fixation Methods of Tacks, Vicryl Suture, and Non-fixation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>189</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45017</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: In addition to the effective treatment of the medical condition subjected to the study, this trial attempts to improve the patients' quality of life and to reduce surgical complications, Randomization description: Simple randomisation by using the table of random numbers, Blinding description: Patients, investigators, and data analyst did not have any knowledge of the patient's assigned study group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Unilateral Inguinal hernia. Condition 2: Bilateral Inguinal hernia. Condition 3: Chronic pain after herniotomy.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Patients undergo general anaesthesia and surgery is performed in Trendelenburg position. Thirty minutes before surgery, one gram of cefazoline is injected intravenously. CO2 Insufflation is performed via an open technique of umbilical 11 mm port insertion. In unilateral repair, two 5 mm ports are installed in midclavicular lines. Insertion point on the ipsilateral side is 2 inches above and on the contralateral side 2 inches below the umbilical line. In bilateral repair, both 5 mm ports are located on the umbilical line. Peritoneal dissection is started at the inferior epigastric vessels site and extended medially to umbilical vessels fold and laterally to ASIS with a maximum size of 13 cm. In the case of direct hernia, the hernia sac is dissected and reduced. In indirect or femoral hernias, Para pubic preperitoneal fat pad is dissected to visualise pubic ramus and cooper ligament. Retrovesical preperitoneal dissection allows for better and easier mesh covering. Internal ring is explored and sac is dissected. After dissection of the spermatic cord from parietal peritoneum, a monofilament propylene 10x15 cm mesh is inserted and embedded in the preperitoneal space. This kind of mesh allows visualisation of underlying tissues. Medially mesh is in contact with paravesical space and laterally with ASIS. In the first group, the mesh is fixed to the inguinal ligament and pubic tubercle with 3-4 tacks. The last step is reperitonealization over the mesh and peritoneal repair. Intervention 2: First intervention group: In the second group, the mesh is spread in the same space, but in the next step, the mesh is fixed with a 2-0 Vickryl suture to a point over the internal ring. Other steps of the operation are carried out the same as the control group. Intervention 3: Second intervention group: In the third group, the exact surgical technique as the control group is applied, except that after mesh placement, fixation is not performed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information currently. Data will be updated.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Sara Aghaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jerib Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۳۴۶۱-۸۱۷۴۶</zip>
        <telephone>+98 31 3668 0048</telephone>
        <email>saraaghaei.nsr@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Behrooz Kleidari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jerib Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۳۴۶۱-۸۱۷۴۶</zip>
        <telephone>+98 31 3668 0048</telephone>
        <email>alagol83@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18, with the diagnosis of uncomplicated primary uni/bilateral reducible inguinal or femoral hernia;
Eligible for elective laparoscopic hernia repair and general anaesthesia, ASA (American Society of Anesthesiologists) score of ≤ 3.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with complicated, incarcerated, strangulated, or recurrent hernia;
Following medical conditions: coagulopathy, immunosuppression, current anticoagulation treatment, current opioid or alcohol substance abuse, ongoing long term treatment with steroids and analgesics, ASA score &gt; 3, and BMI ≥ 35.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K40.90</hc_code>
      <hc_code>K40.20</hc_code>
      <hc_code>G89.28</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unilateral inguinal hernia, without obstruction or gangrene, not specified as recurrent</hc_keyword>
      <hc_keyword>Bilateral inguinal hernia, without obstruction or gangrene, not specified as recurrent</hc_keyword>
      <hc_keyword>Other chronic postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Patients undergo general anaesthesia and surgery is performed in Trendelenburg position. Thirty minutes before surgery, one gram of cefazoline is injected intravenously. CO2 Insufflation is performed via an open technique of umbilical 11 mm port insertion. In unilateral repair, two 5 mm ports are installed in midclavicular lines. Insertion point on the ipsilateral side is 2 inches above and on the contralateral side 2 inches below the umbilical line. In bilateral repair, both 5 mm ports are located on the umbilical line. Peritoneal dissection is started at the inferior epigastric vessels site and extended medially to umbilical vessels fold and laterally to ASIS with a maximum size of 13 cm. In the case of direct hernia, the hernia sac is dissected and reduced. In indirect or femoral hernias, Para pubic preperitoneal fat pad is dissected to visualise pubic ramus and cooper ligament. Retrovesical preperitoneal dissection allows for better and easier mesh covering. Internal ring is explored and sac is dissected. After dissection of the spermatic cord from parietal peritoneum, a monofilament propylene 10x15 cm mesh is inserted and embedded in the preperitoneal space. This kind of mesh allows visualisation of underlying tissues. Medially mesh is in contact with paravesical space and laterally with ASIS. In the first group, the mesh is fixed to the inguinal ligament and pubic tubercle with 3-4 tacks. The last step is reperitonealization over the mesh and peritoneal repair.</i_keyword>
      <i_keyword>First intervention group: In the second group, the mesh is spread in the same space, but in the next step, the mesh is fixed with a 2-0 Vickryl suture to a point over the internal ring. Other steps of the operation are carried out the same as the control group.</i_keyword>
      <i_keyword>Second intervention group: In the third group, the exact surgical technique as the control group is applied, except that after mesh placement, fixation is not performed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Chronic post-herniorrhaphy inguinal pain. Timepoint: 3, 6, and 12 months after surgery. Method of measurement: 100 mm Visual Analogue Scale for assessment of pain intensity.</prim_outcome>
      <prim_outcome>Post-herniorrhaphy quality of life. Timepoint: 12 months after surgery. Method of measurement: The Medical Outcome Survey SF-36 questionnaire for quality of life evaluation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Acute postoperative inguinal pain. Timepoint: 1 and 10 days after surgery. Method of measurement: 100 mm Visual Analogue Scale for assessment of pain intensity.</sec_outcome>
      <sec_outcome>Intraoperative complications. Timepoint: During surgery. Method of measurement: Intraoperative assessments by the surgeon.</sec_outcome>
      <sec_outcome>Postoperative complications including surgical site infection, seroma and hematoma formation, orchitis, and neuralgia. Timepoint: 1 and 10 days, 3, 6, and 12 months after surgery. Method of measurement: Interview with the patient; physical examination.</sec_outcome>
      <sec_outcome>Duration of surgery. Timepoint: During surgery. Method of measurement: Timer.</sec_outcome>
      <sec_outcome>Length of hospital stay. Timepoint: In the first week after surgery. Method of measurement: Recording duration of hospitalization.</sec_outcome>
      <sec_outcome>Duration of analgesic use for the management of postoperative groin pain. Timepoint: 1 and 10 days, 3, 6, and 12 months after surgery. Method of measurement: Interview with the patient.</sec_outcome>
      <sec_outcome>Time of return to normal daily activities. Timepoint: 1 and 10 days, 3, 6, and 12 months after surgery. Method of measurement: Interview with the patient.</sec_outcome>
      <sec_outcome>Recurrence of hernia. Timepoint: 1 and 10 days, 3, 6, and 12 months after surgery. Method of measurement: Interview with the patient; physical examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-01-02</approval_date>
        <contact_name>Research Ethics Committee of Isfahan University of Medical Sciences and Health Services</contact_name>
        <contact_address>Hezar Jerib street Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
